What are examples of antidiabetic agents and their mechanisms of action?

Antidiabetic Medications: Examples and Mechanisms of Action

The major classes of antidiabetic agents work through distinct mechanisms targeting different aspects of glucose metabolism, including insulin secretion, insulin sensitivity, glucose absorption, and glucose excretion. Below is a comprehensive overview organized by drug class with specific examples and their mechanisms 1, 2.

Biguanides

• Example: Metformin
• Mechanism: Decreases hepatic glucose output and enhances primarily hepatic and muscle insulin sensitivity without directly affecting β-cell function 3, 2
• Key Point: Metformin remains the first-line medication for type 2 diabetes due to its high efficacy in lowering HbA1c, good safety profile, minimal hypoglycemia risk, and low cost 1

Sulfonylureas

• Examples: Glyburide, glimepiride, gliclazide, glipizide, tolazamide, tolbutamide, acetohexamide, chlorpropamide 3
• Mechanism: Stimulate insulin secretion from pancreatic β-cells 1, 2
• Key Point: Newer-generation sulfonylureas (glipizide, glimepiride, gliclazide) have lower hypoglycemia risk compared to older agents 1

Meglitinides (Glinides)

• Examples: Repaglinide, nateglinide, mitiglinide 3, 2
• Mechanism: Non-sulfonylurea insulin secretagogues that promote short-term, glucose-stimulated insulin secretion, primarily reducing postprandial blood glucose 3, 2
• Key Point: Must be taken immediately before meals; lower hypoglycemia risk than sulfonylureas 2

Thiazolidinediones (TZDs)

• Examples: Pioglitazone, rosiglitazone 3, 1, 2
• Mechanism: Increase peripheral insulin sensitivity by acting as PPAR-gamma agonists 1, 2
• Key Point: Associated with best evidence for glycemic durability but carry risks of fluid retention, heart failure, weight gain, and bone fractures 1
• Important Caveat: Troglitazone is no longer recommended due to fatal hepatic failure risk 3

α-Glucosidase Inhibitors

• Examples: Acarbose, miglitol, voglibose 3, 2
• Mechanism: Slow hydrolysis of complex carbohydrates and delay carbohydrate absorption in the small intestine 3, 2
• Key Point: Particularly effective for postprandial hyperglycemia in patients consuming high-carbohydrate diets 2

DPP-4 Inhibitors

• Examples: Saxagliptin, alogliptin, sitagliptin, linagliptin 1
• Mechanism: Increase insulin secretion and reduce glucagon secretion in a glucose-dependent manner by inhibiting dipeptidyl peptidase-4 1
• Key Point: Well tolerated with neutral weight effect and minimal hypoglycemia risk as monotherapy; dose adjustment required for renal function except linagliptin 1

GLP-1 Receptor Agonists

• Examples:
  • Once-weekly: Semaglutide, dulaglutide, exenatide extended-release 1
  • Once-daily: Liraglutide, lixisenatide 1
  • Twice-daily: Exenatide 1
• Mechanism: Stimulate insulin secretion and reduce glucagon secretion in a glucose-dependent manner, improve satiety, slow gastric emptying, and promote weight loss 1
• Key Point: High glucose-lowering efficacy with semaglutide showing greatest effect, followed by dulaglutide and liraglutide; minimal hypoglycemia risk; demonstrated cardiovascular benefits 1, 4

SGLT2 Inhibitors

• Examples: Empagliflozin, canagliflozin, dapagliflozin, ertugliflozin 4
• Mechanism: Block sodium-glucose co-transporter 2 in the proximal renal tubule, causing urinary glucose excretion 4
• Key Point: Demonstrated cardiovascular and renal protection benefits; reduce heart failure hospitalization and cardiovascular death 4
• Important Caveats: Risk of genital mycotic infections, diabetic ketoacidosis (rare), acute kidney injury, dehydration; canagliflozin associated with increased amputation and fracture risk 1

Amylin Agonists

• Example: Pramlintide 5
• Mechanism: Synthetic analogue of β-cell hormone amylin; slows gastric emptying, inhibits glucagon production in glucose-dependent fashion, predominantly decreases postprandial glucose 5
• Key Point: Administered subcutaneously before meals; approved only as adjunctive therapy with insulin 5

Insulin

• Types:
  • Basal: NPH, glargine, detemir, degludec
  • Prandial: Regular, lispro, aspart, glulisine
  • Premixed combinations 5, 1
• Mechanism: Directly replaces or supplements endogenous insulin; promotes glucose uptake in muscle and adipose tissue, suppresses hepatic glucose production 5, 1
• Key Point: Most effective glucose-lowering agent with no maximum dose limitation; can decrease any elevated A1C to near-target levels; associated with weight gain and hypoglycemia risk 5, 1

Clinical Considerations

Combination therapy is often necessary as type 2 diabetes is a progressive disease. Agents with complementary mechanisms (e.g., metformin + sulfonylurea, metformin + GLP-1 RA) provide additive glucose-lowering effects 1, 6.

Cardiovascular and renal protection: GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated benefits beyond glucose lowering, including reduction in major adverse cardiovascular events and progression of kidney disease 4, 6.

Hypoglycemia risk hierarchy: Insulin and sulfonylureas carry highest risk; meglitinides moderate risk; metformin, TZDs, DPP-4 inhibitors, GLP-1 RAs, SGLT2 inhibitors, and α-glucosidase inhibitors have minimal risk when used as monotherapy 1.